U.S. Genomics renames to Pathogenetix, raises $1.3M
U.S. Genomics, a pathogen-diagnostic technologies firm in Woburn, has changed its name to Pathogenetix Inc. The name change was noted in a regulatory filing with the U.S. Securities and Exchange Commission, in which the company reported it had raised $1.3 million in an equity offering and converted $900,000 in debt.
Pathogenetix does not yet have a working website and the U.S. Genomics website and phone number were down, as of Friday morning. David Hoey, vice president of business development at the company, said by phone that the disruptions were temporary and due to a company move within its Woburn site.